![](/img/cover-not-exists.png)
Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib
Boquimpani, Carla, Schaffel, Rony, Biasoli, Irene, Bendit, Israel, Spector, NelsonVolume:
56
Language:
english
Journal:
Leukemia & Lymphoma
DOI:
10.3109/10428194.2014.974047
Date:
June, 2015
File:
PDF, 715 KB
english, 2015